1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Galectin Therapeutics - Product Pipeline Review - 2013

Galectin Therapeutics - Product Pipeline Review - 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 30 pages

Galectin Therapeutics - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Galectin Therapeutics - Product Pipeline Review - 2013” provides data on the Galectin Therapeutics’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Galectin Therapeutics’s corporate website, SEC filings, investor presentations and featured press releases, both from Galectin Therapeutics and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Galectin Therapeutics - Brief Galectin Therapeutics overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Galectin Therapeutics human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Galectin Therapeutics with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Galectin Therapeutics’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Galectin Therapeutics’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Galectin Therapeutics in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Galectin Therapeutics’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Galectin Therapeutics.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Galectin Therapeutics and identify potential opportunities in those areas.

Table Of Contents

Galectin Therapeutics - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Galectin Therapeutics Snapshot 4
Key Information 4
Key Facts 4
Galectin Therapeutics - Research and Development Overview 5
Key Therapeutic Areas 5
Galectin Therapeutics - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Galectin Therapeutics Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Galectin Therapeutics - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Galectin Therapeutics - Drug Profiles 13
GM-CT-01 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
GM-CT-02 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
GR-MD-01 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
GR-MD-02 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Galectin Therapeutics - Pipeline Analysis 17
Galectin Therapeutics - Pipeline Products by Therapeutic Class 17
Galectin Therapeutics - Pipeline Products By Target 19
Galectin Therapeutics - Pipeline Products by Route of Administration 20
Galectin Therapeutics - Pipeline Products By Mechanism of Action 21
Galectin Therapeutics - Recent Pipeline Updates 22
Galectin Therapeutics - Dormant Projects 27
Galectin Therapeutics - Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30



List of Tables

Galectin Therapeutics, Key Information 4
Galectin Therapeutics, Key Facts 4
Galectin Therapeutics - Pipeline by Indication, 2013 7
Galectin Therapeutics - Pipeline by Stage of Development, 2013 8
Galectin Therapeutics - Monotherapy Products in Pipeline, 2013 9
Galectin Therapeutics - Phase II, 2013 10
Galectin Therapeutics - Phase I, 2013 11
Galectin Therapeutics - Preclinical, 2013 12
Galectin Therapeutics - Pipeline By Therapeutic Class, 2013 18
Galectin Therapeutics - Pipeline By Target, 2013 19
Galectin Therapeutics - Pipeline By Route of Administration, 2013 20
Galectin Therapeutics - Pipeline Products By Mechanism of Action, 2013 21
Galectin Therapeutics - Recent Pipeline Updates, 2013 22
Galectin Therapeutics - Dormant Developmental Projects,2013 27



List of Figures

Galectin Therapeutics - Pipeline by Indication, 2013 6
Galectin Therapeutics - Pipeline by Stage of Development, 2013 8
Galectin Therapeutics - Monotherapy Products in Pipeline, 2013 9
Galectin Therapeutics - Pipeline By Therapeutic Class, 2013 17
Galectin Therapeutics - Pipeline By Route of Administration, 2013 20
Galectin Therapeutics - Pipeline Products By Mechanism of Action, 2013 21



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.